Clinical Trials Directory

Trials / Completed

CompletedNCT02056496

Pharmacokinetics and Bioavailability of Pomegranate Phenolics and Urolithins in Healthy Subjects.

Pharmacokinetics and Bioavailability of Pomegranate Phenolics and Gut Microbiota-derived Metabolites (Urolithins) in Overweight Subjects. Comparison Between Two Pomegranate Extracts

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
National Research Council, Spain · Other Government
Sex
All
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

Pomegranate phenolics (such as the ellagitannin punicalagin and ellagic acid) are metabolized by the human gut microbiota to yield a number of metabolites called urolithins (mainly Uro-A). Both ellagic acid (EA) and urolithins can exert a number of biological activities. However, the bioavailability of ellagic acid has been reported to be very low and the existing studies are controversial so far. The investigators want to carry out a robust (cross-over, double-blind) pharmacokinetic assay in 20 healthy volunteers, using two types of pomegranate extracts (PEs). PEs with low (PE-1) and high (PE-2) punicalagin:EA ratio will be administered. The investigators will analyze blood and urine samples using UPLC-ESI-QTOF-MS/MS. The investigators will evaluate: * The pharmacokinetics of EA. * The effect of punicalagin:free EA ratio on the pharmacokinetics of EA and urolithins production.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPomegranate extractCrossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
DIETARY_SUPPLEMENTPomegranate extractCrossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).

Timeline

Start date
2014-01-01
Primary completion
2014-01-01
Completion
2014-02-01
First posted
2014-02-06
Last updated
2015-04-14

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT02056496. Inclusion in this directory is not an endorsement.